Related Funds
| Fund Name | Location |
| aMoon2 Fund | - |
| Cambium Grove Capital | - |
| Digital China | Beijing, China, Haidian |
| Edelweiss Alternative Asset Advisors | - |
| Heyong Touzi | China, Fujian, Xiamen |
| Hitachi Global Life Solutions | Japan, Shibuya |
| Kateeva | California, Newark, United States |
| Kyocera Corporation | Japan, Kyoto, Kyoto Prefecture |
| Lodestar Ventures | California, San Francisco, United States |
| Manna Tree | Colorado, United States, Vail |
| Mingyuan Hongqiao Investment Management | China, Fujian, Xiamen |
| Onventures | Columbus, Ohio, United States |
| RG Capital Management | Arizona, Phoenix, United States |
| SB Media Holdings | Japan, Tokyo |
| Smart Sparks Angel Network | Calicut, India, Kerala |
| Stanley Family Foundation | Iowa, Muscatine, United States |
| Summer Wind Capital | New York, New York, United States |
| Women's World Banking | New York, New York, United States |
| Xiwo Zhongchuang Kongjian | China, Jiangsu, Wuxi Shi |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
IGEM Therapeutics | $42M | 02 Mar 2022 | London, England, United Kingdom | ||
Macomics | $5M | 29 Jul 2021 | City of Edinburgh, Scotland, United Kingdom |
– Macomics Ltd has closed a follow-on financing of £4.24m from its 2020 Seed round, bringing the total amount raised to £7.44m.
– The additional investment brings in new investor Caribou Property Limited alongside existing investors Epidarex Capital, who led the round, and Scottish Enterprise.
– It will be used to accelerate the company’s growth, including expansion of the team.
– Macomics is developing precision medicines to modulate macrophages for the treatment of cancer.
– The company was co-founded in 2019 by Prof Jeffrey Pollard and Dr Luca Cassetta, University of Edinburgh, internationally recognised leaders in macrophage biology.
– It is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages (‘TAMs’) towards the clinic.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
IGEM Therapeutics | $42M | 02 Mar 2022 | London, England, United Kingdom | ||
Macomics | $5M | 29 Jul 2021 | City of Edinburgh, Scotland, United Kingdom |
